Showing results (261-270 of 317) with videos related to

Sort By:
Pageof 32
European Urology Oncology|February 26, 2022
TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant CellsJonathan Chou, Kai Trepka, Martin Sjöström, et al.
Future Oncology (London, England)|September 17, 2020
PIVOT-10: Phase II study of bempegaldesleukin plus nivolumab in cisplatin-ineligible advanced urothelial cancerRobert A Huddart, Arlene O Siefker-Radtke, Arjun V Balar, et al.
Frontiers in Oncology|April 24, 2023
Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancerTanya Jindal, Xiaolin Zhu, Rohit Bose, et al.
The Lancet. Oncology|June 3, 2023
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trialKarim Fizazi, Ken Herrmann, Bernd J Krause, et al.
Journal for Immunotherapy of Cancer|May 13, 2021
TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitorIvan de Kouchkovsky, Li Zhang, Errol J Philip, et al.
The Journal of Urology|September 16, 2020
Sequencing of PD-1/L1 Inhibitors and Carboplatin Based Chemotherapy for Cisplatin Ineligible Metastatic Urothelial CarcinomaXiao X Wei, Lillian Werner, Min Y Teo, et al.
Cancer Medicine|October 12, 2021
Feasibility, safety, and acceptability of a remotely monitored exercise pilot CHAMP: A Clinical trial of High-intensity Aerobic and resistance exercise for Metastatic castrate-resistant Prostate cancerStacey A Kenfield, Erin L Van Blarigan, Neil Panchal, et al.
JCO Precision Oncology|August 23, 2024
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair GenesLaura S Graham, Nicholas C Henderson, Olesia Kellezi, et al.
Urologic Oncology|December 17, 2022
Quality of life for men with metastatic castrate-resistant prostate cancer participating in an aerobic and resistance exercise pilot interventionCrystal S Langlais, Yea-Hung Chen, Erin L Van Blarigan, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2024
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancerAmanda Broderick, Elizabeth Pan, Jinju Li, et al.
Pageof 32